35183303 35086794 35430025 35569886 35625757 35013596 35650449 35080136 - Search Results

1

A global view of the interplay between non-alcoholic fatty liver disease and diabetes.

Stefan N, Cusi K. Stefan N, et al. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296. doi: 10.1016/S2213-8587(22)00003-1. Epub 2022 Feb 17. Lancet Diabetes Endocrinol. 2022. PMID: 35183303 Review.

2

Metabolic dysfunction-associated fatty liver disease - How relevant is this to primary care physicians and diabetologists?

Lee CH. Lee CH. Prim Care Diabetes. 2022 Apr;16(2):245-251. doi: 10.1016/j.pcd.2022.01.005. Epub 2022 Jan 25. Prim Care Diabetes. 2022. PMID: 35086794 Review.

3

JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk.

Wyne KL, Litwin SE, Cusi K, Guyton JR. Wyne KL, et al. J Clin Lipidol. 2022 Mar-Apr;16(2):115-127. doi: 10.1016/j.jacl.2022.03.007. J Clin Lipidol. 2022. PMID: 35430025

4

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Cusi K, et al. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010. Endocr Pract. 2022. PMID: 35569886 Review.

5

Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism.

Errafii K, Khalifa O, Al-Akl NS, Arredouani A. Errafii K, et al. Biomedicines. 2022 Apr 28;10(5):1020. doi: 10.3390/biomedicines10051020. Biomedicines. 2022. PMID: 35625757 Free PMC article.

6

Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ, Zheng MH. Wang TY, et al. Nat Rev Nephrol. 2022 Apr;18(4):259-268. doi: 10.1038/s41581-021-00519-y. Epub 2022 Jan 10. Nat Rev Nephrol. 2022. PMID: 35013596 Review.

7

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.

Mahapatra MK, Karuppasamy M, Sahoo BM. Mahapatra MK, et al. Pharm Res. 2022 Jun;39(6):1233-1248. doi: 10.1007/s11095-022-03302-1. Epub 2022 Jun 1. Pharm Res. 2022. PMID: 35650449 Free PMC article. Review.

8

Non-alcoholic fatty liver disease and type 2 diabetes: An update.

Lee CH, Lui DT, Lam KS. Lee CH, et al. J Diabetes Investig. 2022 Jun;13(6):930-940. doi: 10.1111/jdi.13756. Epub 2022 Feb 14. J Diabetes Investig. 2022. PMID: 35080136 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results